Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...

Yeztugo showed promising results in clinical trials. One study involving women in Africa reported 100% efficacy, with zero ...

The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...

He affirmed that the new drug "could take the epidemic to the history books," according to Mother Jones.Yeztugo, based on the ...

The FDA has approved Yeztugo for PrEP to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35kg.

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.

The new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or ...

In clinical trials, the drug nearly eliminated HIV’s spread among people given an injection every six months. Called Yeztugo, the highly effective drug has inspired feverish anticipation among ...

FDA approves Yeztugo HIV prevention injection showing 96% efficacy in clinical trials, but $14,000 cost creates significant ...

June 19, 2025 – The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections.

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...